Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADJUST: adjustable versus standard brodalumab dosing in obese adults with moderate-to-severe plaque psoriasis
NL-OMON56463Phase 4Completed
- Sponsor
- LEO Pharma
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of brodalumab in plaque psoriasis, sponsored by LEO Pharma. Primary endpoint: PASI 90 response at Week 40. Started Jul 2022; status: completed.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON56463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56463.